evrazkarЕвразийский Кардиологический ЖурналEurasian heart journal2225-16852305-0748Евразийская ассоциация кардиологов10.38109/2225-1685-2021-1-106-117evrazkar-6258Research ArticleОБЗОРЫREVIEWSМЕТАБОЛОМНЫЕ ПОДХОДЫ В ИЗУЧЕНИИ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙMETABOLOMIC APPROACHES IN STUDYING OF CARDIOVASCULAR DISEASEShttps://orcid.org/0000-0002-8268-7699АбдуллаевА. А.АbdullaevA. A.

заместитель директора, доктор биологических наук

ул. Талабалар Шахарчаси, 3а. 100174, г. Ташкент

100000, Ташкент. Мирзо-улугбековский район, ул. Исмоилий, 2-23

Prof., Dr. of Sci. (Bio.), Biotechnology Laboratory, deputy director

Talabalar shaharchasi street 3A, 100174, Tashkent

abdullaev_alisher@yahoo.comhttps://orcid.org/0000-0003-3840-5233АбдуллаеваГ. Ж.АbdullaevaG. J.

ведущий научный сотрудник, доктор медицинских наук, лаборатория артериальной гипертонии

ул. Осие 4, 100052, г. Ташкент

Cand. of Sci. (Med.), Artherial Hypertension Laboratory

Osie 4 street, 100052, Tashkent

https://orcid.org/0000-0003-2266-7431ЮсуповаХ. Ф.UsupovaKh. F.

младший научный сотрудник, лаборатория артериальной гипертонии

ул. Осие 4, 100052, г. Ташкент

Prof., Dr. of Sci. (Bio.), Biotechnology Laboratory

Osie 4 street, 100052, Tashkent

Центр Передовых Технологий при Министерстве инновационного развития РеспубликиУзбекистанCenter for Advanced Technologies, Ministry of Innovative Development of UzbekistanUzbekistanРеспубликанский специализированный научно-практический медицинский центр кардиологии при Министерстве здравоохранения Республики УзбекистанУзбекистанRepublican Specialized Scientific and Practical Medical Center of Cardiology at Ministry of HealthUzbekistan20213003202101106117Copyright © Абдуллаев А.А., Абдуллаева Г.Ж., Юсупова Х.Ф., 20212021Абдуллаев А.А., Абдуллаева Г.Ж., Юсупова Х.Ф.Аbdullaev A.A., Аbdullaeva G.J., Usupova K.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.heartj.asia/jour/article/view/6258

Современные научные достижения дают клиницистам преимущество в использовании дополнительных инструментов и методов оказания помощи в клинической оценке и расширения их возможностей для классификации пациентов по факторам риска сердечно-сосудистых осложнений. Биомаркеры – это простой инструмент, позволяющий идентифицировать и классифицировать людей с различной степенью риска, быстро и точно диагностировать состояние болезни, эффективно прогнозировать и контролировать лечение. Следовательно, изучение биомаркеров является серьезным и перспективным подходом к пониманию и лечению ССЗ. Среди них особое место занимают генетические и биохимические маркеры. Кардио-метаболомика является новой наукой, которая позволяет исследователям изучать изменения в метаболоме и метаболических сетях, при заболеваниях сердечнососудистой системы, чтобы лучше понять их патофизиологический механизм. Таким образом, изучение метаболома может дать важную информацию о патогенезе сердечно-сосудистых заболеваний, а также предложить возможность выявления новых биомаркеров ССЗ.

Modern scientific approaches give clinicians an advantage in using additional tools and methods for assisting in clinical assessment and expanding their capabilities for classifying patients according to risk factors for cardiovascular complications. Biomarkers are a simple tool that allows to identify and classify people with different risk degree, quickly and accurately diagnose the condition of the disease, effectively predict and control treatment. Therefore, the identification and study of biomarkers is a serious and promising approach to understanding and treating cardiovascular diseases (CVD). Among a wide range of biomarkers, the genetic and metabolic markers is of high importance. Cardio-metabolomics is a new direction in cardiovascular science that allows researchers to study changes in metabolome and metabolic networks in diseases of the cardiovascular system in order to better understand their pathophysiological mechanism. Thus, the study of metabolome can provide important information about the pathogenesis of CVDs, as well as offer the possibility of identifying new CVD biomarkers.

биомаркерыметаболомикаомикссердечно-сосудистые заболеваниягипертрофия сердечной мышцысердечная недостаточностьbiomarkersmetabolomicsomicscardiovascular diseasescardiac muscle hypertrophyheart failureReferencesWorld Health Organization. 2020. https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1World Health Organization. 2020. https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1Panju A.A., Hemmelgarn B.R., Guyatt G.H. et al. Is this patient having a myocardial infarction? JAMA. 1996; 280 (14): 1256–1263.Panju A.A., Hemmelgarn B.R., Guyatt G.H. et al. Is this patient having a myocardial infarction? JAMA. 1996; 280 (14): 1256–1263.Pope J.H., Aufderheide T.P., Ruthazer R. et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N. Engl. J. Med. 2000; 342 (16): 1163–1170.Pope J.H., Aufderheide T.P., Ruthazer R. et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N. Engl. J. Med. 2000; 342 (16): 1163–1170.Naghavi M., Libby P., Falk E. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation. 2003; 108 (15): 1772–1778.Naghavi M., Libby P., Falk E. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation. 2003; 108 (15): 1772–1778.Wishart D.S., Feunang Y.D., Marcu A. et al. HMDB 4.0 — The Human Metabolome Database for 2018. Nucleic Acids Res. 2018. Jan 4; 46(D1): D 608-17. 29140435.Wishart D.S., Feunang Y.D., Marcu A. et al. HMDB 4.0 — The Human Metabolome Database for 2018. Nucleic Acids Res. 2018. Jan 4; 46(D1): D 608-17. 29140435.Ellis D. I., Dunn W. B., Griffin J. L. et al. “Metabolic fingerprinting as a diagnostic tool”. Pharmacogenomics. 2007; vol. 8, № 9: 1243–1266.Ellis D. I., Dunn W. B., Griffin J. L. et al. “Metabolic fingerprinting as a diagnostic tool”. Pharmacogenomics. 2007; vol. 8, № 9: 1243–1266.Tweeddale H., Notley-McRobb L., Ferenci T. Effect of slow growth on metabolism of Escherichia coli, as revealed by global metabolite pool («metabolome») analysis. J. Bacteriol. 1998; 180(19):5109-16.Tweeddale H., Notley-McRobb L., Ferenci T. Effect of slow growth on metabolism of Escherichia coli, as revealed by global metabolite pool («metabolome») analysis. J. Bacteriol. 1998; 180(19):5109-16.Sabatine M.S., Liu E., Morrow D.A. et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation. 2005; 112: 3868–3875. doi: 10.1161/CIRCULATIONAHA.105.569137.Sabatine M.S., Liu E., Morrow D.A. et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation. 2005; 112: 3868–3875. doi: 10.1161/CIRCULATIONAHA.105.569137.Griffin J. L., Atherton H., Shockcor J. et al. “Metabolomics as a tool for cardiac research”. Nature Reviews Cardiology. 2011; vol. 8, no. 11: 630–643.Griffin J. L., Atherton H., Shockcor J. et al. “Metabolomics as a tool for cardiac research”. Nature Reviews Cardiology. 2011; vol. 8, no. 11: 630–643.Wishart D.S., Jewison T, Guo A.C. et al. HMDB 3.0–the human metabolome database in 2013. Nucleic Acids Res. 2013; 41: 801–807.Wishart D.S., Jewison T, Guo A.C. et al. HMDB 3.0–the human metabolome database in 2013. Nucleic Acids Res. 2013; 41: 801–807.Cheng S., Shah S.H., Corwin E.J., et al. Potential impact and study considerations of metabolomics in cardiovascular health and disease: a scientific statement from the American Heart Association. Circ. Cardiovasc. Genet. 2017; 10: e000032.Cheng S., Shah S.H., Corwin E.J., et al. Potential impact and study considerations of metabolomics in cardiovascular health and disease: a scientific statement from the American Heart Association. Circ. Cardiovasc. Genet. 2017; 10: e000032.Allard M.F., Schönekess B.O., Henning S.L. et al. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am. J. Physiol. 1994; 267: 742–750.Allard M.F., Schönekess B.O., Henning S.L. et al. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am. J. Physiol. 1994; 267: 742–750.Burelle Y., Wambolt R.B., Grist M. et al. Regular exercise is associated with a protective metabolic phenotype inthe rat heart. Am J Physiol Heart Circ Physiol. 2004; 287: 1055–1063.Burelle Y., Wambolt R.B., Grist M. et al. Regular exercise is associated with a protective metabolic phenotype inthe rat heart. Am J Physiol Heart Circ Physiol. 2004; 287: 1055–1063.Lai L., Leone T.C., Keller M.P. et al. Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. Circ. Heart Fail. 2014; 7: 1022–1031.Lai L., Leone T.C., Keller M.P. et al. Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. Circ. Heart Fail. 2014; 7: 1022–1031.Kato T., Niizuma S., Inuzuka Y. et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ. Heart Fail. 2010; 3: 420–430.Kato T., Niizuma S., Inuzuka Y. et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ. Heart Fail. 2010; 3: 420–430.Meerson F.Z., Spiritchev V.B., Pshennikova M.G. et al. The role of the pentose-phosphate pathway in adjustment of the heart to ahigh load and the development of myocardial hypertrophy. Experientia. 1967; 23: 530–532.Meerson F.Z., Spiritchev V.B., Pshennikova M.G. et al. The role of the pentose-phosphate pathway in adjustment of the heart to ahigh load and the development of myocardial hypertrophy. Experientia. 1967; 23: 530–532.Zimmer H.G., Ibel H., Steinkopff G. Studies on the hexose monophosphate shunt in the myocardium during development of hypertrophy. Adv. Myocardiol. 1980; 1: 487–492.Zimmer H.G., Ibel H., Steinkopff G. Studies on the hexose monophosphate shunt in the myocardium during development of hypertrophy. Adv. Myocardiol. 1980; 1: 487–492.Leong H.S., Grist M., Parsons H. et al. Accelerated rates of glycolysis in the hypertrophied heart: are they a methodological artifact? Am J Physiol. Endocrinol. Metab. 2002; 282: 1039–1045.Leong H.S., Grist M., Parsons H. et al. Accelerated rates of glycolysis in the hypertrophied heart: are they a methodological artifact? Am J Physiol. Endocrinol. Metab. 2002; 282: 1039–1045.Young M.E., Yan J., Razeghi P. et al. Proposed regulation of gene expression by glucose in rodent heart. Gene Regul. Syst. Bio. 2007; 1: 251–262.Young M.E., Yan J., Razeghi P. et al. Proposed regulation of gene expression by glucose in rodent heart. Gene Regul. Syst. Bio. 2007; 1: 251–262.Kolwicz S.C.Jr., Tian R. Glucose metabolism and cardiac hypertrophy. Cardiovasc. Res. 2011; 90: 194–201.Kolwicz S.C.Jr., Tian R. Glucose metabolism and cardiac hypertrophy. Cardiovasc. Res. 2011; 90: 194–201.Doenst T., Nguyen T.D., Abel E.D. Cardiac metabolism in heart failure: Implications beyond ATP production. Circ Res. 2013; 113: 709–724.Doenst T., Nguyen T.D., Abel E.D. Cardiac metabolism in heart failure: Implications beyond ATP production. Circ Res. 2013; 113: 709–724.Ussher J.R., Elmariah S., Gerszten R.E. et al. The emerging role of metabolomics in the diagnosis and prognosis of cardiovascular disease. J. Am. Coll. Cardiol. 2016; 68: 2850–2870.Ussher J.R., Elmariah S., Gerszten R.E. et al. The emerging role of metabolomics in the diagnosis and prognosis of cardiovascular disease. J. Am. Coll. Cardiol. 2016; 68: 2850–2870.De Jong K.A., Lopaschuk G.D. Complex energy metabolic changes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Can. J. Cardiol. 2017; 33: 860–871.De Jong K.A., Lopaschuk G.D. Complex energy metabolic changes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Can. J. Cardiol. 2017; 33: 860–871.Neubauer S. The failing heart–an engine out of fuel. N. Engl. J. Med. 2007; 356: 1140–1151.Neubauer S. The failing heart–an engine out of fuel. N. Engl. J. Med. 2007; 356: 1140–1151.Nascimben L., Ingwall J.S., Pauletto P. et al. Creatine kinase system in failing and nonfailing human myocardium. Circulation. 1996; 94: 1894–1901.Nascimben L., Ingwall J.S., Pauletto P. et al. Creatine kinase system in failing and nonfailing human myocardium. Circulation. 1996; 94: 1894–1901.van Bilsen M., van Nieuwenhoven F.A., van der Vusse G.J. Metabolic remodelling of the failing heart: beneficial or detrimental? Cardiovasc. Res.2009; 81: 420–428.van Bilsen M., van Nieuwenhoven F.A., van der Vusse G.J. Metabolic remodelling of the failing heart: beneficial or detrimental? Cardiovasc. Res.2009; 81: 420–428.Scheubel R.J., Tostlebe M., Simm A. et al. Dysfunction of mitochondrial respiratory chain complex I in human failing myocardium is not due to disturbed mitochondrial gene expression. J. Am. Coll. Cardiol. 2002; 40: 2174–2181.Scheubel R.J., Tostlebe M., Simm A. et al. Dysfunction of mitochondrial respiratory chain complex I in human failing myocardium is not due to disturbed mitochondrial gene expression. J. Am. Coll. Cardiol. 2002; 40: 2174–2181.Gupte A.A., Hamilton D.J., Cordero-Reyes A.M. et al. Mechanical unloading promotes myocardial energy recovery in human heart failure. Circ. Cardiovasc. Genet. 2014; 7: 266–276.Gupte A.A., Hamilton D.J., Cordero-Reyes A.M. et al. Mechanical unloading promotes myocardial energy recovery in human heart failure. Circ. Cardiovasc. Genet. 2014; 7: 266–276.Sansbury B.E., DeMartino A.M., Xie Z. et al. Metabolomic analysis of pressure-overloaded and infarcted mouse hearts. Circ. Heart. Fail. 2014; 7: 634–642.Sansbury B.E., DeMartino A.M., Xie Z. et al. Metabolomic analysis of pressure-overloaded and infarcted mouse hearts. Circ. Heart. Fail. 2014; 7: 634–642.Sun H., Olson K.C., Gao C. et al. Catabolic defect of branched-chain amino acids promotes heart failure. Circulation. 2016; 133: 2038–2049. doi:10.1161/CIRCULATIONAHA.115.020226.Sun H., Olson K.C., Gao C. et al. Catabolic defect of branched-chain amino acids promotes heart failure. Circulation. 2016; 133: 2038–2049. doi:10.1161/CIRCULATIONAHA.115.020226.Aubert G., Martin O.J., Horton J.L. et al. The failing heart relies on ketone bodies as a fuel. Circulation. 2016; 133: CIRCULATIONAHA.115.017355.Aubert G., Martin O.J., Horton J.L. et al. The failing heart relies on ketone bodies as a fuel. Circulation. 2016; 133: CIRCULATIONAHA.115.017355.Bedi K.C. Jr., Snyder N.W., Brandimarto J. et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation. 2016; 133: 706–716. doi: 10.1161/CIRCULATIONAHA.115.017545.Bedi K.C. Jr., Snyder N.W., Brandimarto J. et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation. 2016; 133: 706–716. doi: 10.1161/CIRCULATIONAHA.115.017545.Ferrara C.T., Wang P., Neto EC. et al. Genetic networks of liver metabolism revealed by integration of metabolic and transcriptional profiling. PLoS Genet. 2008. doi: 10.1371/journal.pgen.1000034.Ferrara C.T., Wang P., Neto EC. et al. Genetic networks of liver metabolism revealed by integration of metabolic and transcriptional profiling. PLoS Genet. 2008. doi: 10.1371/journal.pgen.1000034.Hunter W.G., Kelly J.P., McGarrah RW III. et al. Metabolic dysfunction in heart failure: diagnostic, prognostic, and pathophysiologic insights from metabolomic profiling. Curr. Heart Fail. Rep. 2016; 13: 119–131. doi: 10.1007/s11897-016-0289-5.Hunter W.G., Kelly J.P., McGarrah RW III. et al. Metabolic dysfunction in heart failure: diagnostic, prognostic, and pathophysiologic insights from metabolomic profiling. Curr. Heart Fail. Rep. 2016; 13: 119–131. doi: 10.1007/s11897-016-0289-5.Doehner W., Frenneaux M., Anker SD. Metabolic impairment in heart failure: the myocardial and systemic perspective. J. Am. Coll. Cardiol. 2014; 64: 1388–1400. doi: 10.1016/j.jacc.2014.04.083.Doehner W., Frenneaux M., Anker SD. Metabolic impairment in heart failure: the myocardial and systemic perspective. J. Am. Coll. Cardiol. 2014; 64: 1388–1400. doi: 10.1016/j.jacc.2014.04.083.Ahmad T., Kelly JP., McGarrah RW. et al. Prognostic implications of longchain acylcarnitines in heart failure and reversibility with mechanical circulatory support. J. Am. Coll. Cardiol. 2016; 67: 291–299. doi:10.1016/j.jacc.2015.10.079.Ahmad T., Kelly JP., McGarrah RW. et al. Prognostic implications of longchain acylcarnitines in heart failure and reversibility with mechanical circulatory support. J. Am. Coll. Cardiol. 2016; 67: 291–299. doi:10.1016/j.jacc.2015.10.079.Hinterwirth H., Stegemann C., Mayr M. Lipidomics: quest for molecular lipid biomarkers in cardiovascular disease. Circ. Cardiovasc. Genet. 2014; 7: 941–954. doi: 10.1161/CIRCGENETICS.114.000550.Hinterwirth H., Stegemann C., Mayr M. Lipidomics: quest for molecular lipid biomarkers in cardiovascular disease. Circ. Cardiovasc. Genet. 2014; 7: 941–954. doi: 10.1161/CIRCGENETICS.114.000550.Sparagna G.C., Lesnefsky E.J. Cardiolipin remodeling in the heart. J. Cardiovasc Pharmacol. 2009; 53: 290–301. doi: 10.1097/FJC.0b013e31819b5461.Sparagna G.C., Lesnefsky E.J. Cardiolipin remodeling in the heart. J. Cardiovasc Pharmacol. 2009; 53: 290–301. doi: 10.1097/FJC.0b013e31819b5461.Saini-Chohan H.K., Holmes M.G., Chicco A.J. et al. Cardiolipin biosynthesis and remodeling enzymes are altered during development of heart failure. J. Lipid Res. 2009; 50: 1600–1608. doi: 10.1194/jlr.M800561-JLR200.Saini-Chohan H.K., Holmes M.G., Chicco A.J. et al. Cardiolipin biosynthesis and remodeling enzymes are altered during development of heart failure. J. Lipid Res. 2009; 50: 1600–1608. doi: 10.1194/jlr.M800561-JLR200.Han X., Yang J., Cheng H. et al. Shotgun lipidomics identifies cardiolipin depletion in diabetic myocardium linking altered substrate utilization with mitochondrial dysfunction. Biochemistry. 2005; 44: 16684–16694. doi: 10.1021/bi051908a.Han X., Yang J., Cheng H. et al. Shotgun lipidomics identifies cardiolipin depletion in diabetic myocardium linking altered substrate utilization with mitochondrial dysfunction. Biochemistry. 2005; 44: 16684–16694. doi: 10.1021/bi051908a.Benjamin E.J., Blaha M.J., Chiuve S.E. et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017; 135: 146–603. doi:10.1161/CIR.0000000000000485.Benjamin E.J., Blaha M.J., Chiuve S.E. et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017; 135: 146–603. doi:10.1161/CIR.0000000000000485.Stanley W.C., Recchia F.A., Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 2005; 85: 1093–1129. doi: 10.1152/physrev.00006.2004.Stanley W.C., Recchia F.A., Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 2005; 85: 1093–1129. doi: 10.1152/physrev.00006.2004.Lopaschuk G. Regulation of carbohydrate metabolism in ischemia and reperfusion. Am. Heart J. 2000; 139: 115–119.Lopaschuk G. Regulation of carbohydrate metabolism in ischemia and reperfusion. Am. Heart J. 2000; 139: 115–119.Lopaschuk G.D., Ussher J.R., Folmes C.D. et al. Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 2010; 90: 207–258. doi: 10.1152/physrev.00015.2009.Lopaschuk G.D., Ussher J.R., Folmes C.D. et al. Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 2010; 90: 207–258. doi: 10.1152/physrev.00015.2009.Chouchani E.T., Pell V.R., Gaude E. et al. Ischemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014; 515: 431–435. doi: 10.1038/nature13909.Chouchani E.T., Pell V.R., Gaude E. et al. Ischemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014; 515: 431–435. doi: 10.1038/nature13909.Li T., Zhang Z., Kolwicz SC.Jr. et al. Defective branched-chain amino acid catabolism disrupts glucose metabolism and sensitizes the heart to ischemia-reperfusion injury. Cell Metab. 2017; 25: 374–385. doi:10.1016/j.cmet.2016.11.005.Li T., Zhang Z., Kolwicz SC.Jr. et al. Defective branched-chain amino acid catabolism disrupts glucose metabolism and sensitizes the heart to ischemia-reperfusion injury. Cell Metab. 2017; 25: 374–385. doi:10.1016/j.cmet.2016.11.005.Gao, X., Ke, C., Liu, H. et al. Large-scale Metabolomic Analysis Reveals Potential Biomarkers for Early Stage Coronary Atherosclerosis. Sci. Rep. 2017; 7: 11817. https://doi.org/10.1038/s41598-017-12254-1Gao, X., Ke, C., Liu, H. et al. Large-scale Metabolomic Analysis Reveals Potential Biomarkers for Early Stage Coronary Atherosclerosis. Sci. Rep. 2017; 7: 11817. https://doi.org/10.1038/s41598-017-12254-1Newgard C.B. Metabolomics and metabolic diseases: where do we stand? Cell Metab. 2017; 25: 43–56. doi: 10.1016/j.cmet.2016.09.018.Newgard C.B. Metabolomics and metabolic diseases: where do we stand? Cell Metab. 2017; 25: 43–56. doi: 10.1016/j.cmet.2016.09.018.Felig P., Marliss E., Cahill GF.Jr. Plasma amino acid levels and insulin secretion in obesity. N Engl. J. Med. 1969; 281: 811–816. doi:10.1056/NEJM196910092811503.Felig P., Marliss E., Cahill GF.Jr. Plasma amino acid levels and insulin secretion in obesity. N Engl. J. Med. 1969; 281: 811–816. doi:10.1056/NEJM196910092811503.Newgard C.B., An J., Bain J.R. et al. A branched-chain amino acidrelated metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009; 9: 311–326. doi:10.1016/j.cmet.2009.02.002.Newgard C.B., An J., Bain J.R. et al. A branched-chain amino acidrelated metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009; 9: 311–326. doi:10.1016/j.cmet.2009.02.002.White P.J., Lapworth A.L., An J. et al. Branched-chain amino acid restriction inZucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export. Mol. Metab. 2016; 5: 538–551. doi: 10.1016/j.molmet.2016.04.006.White P.J., Lapworth A.L., An J. et al. Branched-chain amino acid restriction inZucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export. Mol. Metab. 2016; 5: 538–551. doi: 10.1016/j.molmet.2016.04.006.Shaham O., Wei R., Wang T.J. et al Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol. Syst. Biol. 2008; 4: 214. doi: 10.1038/msb.2008.50.Shaham O., Wei R., Wang T.J. et al Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol. Syst. Biol. 2008; 4: 214. doi: 10.1038/msb.2008.50.Huffman K.M., Shah S.H., Stevens R.D. et al. Relationships between circulating metabolic intermediates and insulinaction in overweight to obese, inactive men and women. Diabetes Care. 2009; 32: 1678–1683. doi: 10.2337/dc08-2075.Huffman K.M., Shah S.H., Stevens R.D. et al. Relationships between circulating metabolic intermediates and insulinaction in overweight to obese, inactive men and women. Diabetes Care. 2009; 32: 1678–1683. doi: 10.2337/dc08-2075.Tai E.S., Tan M.L., Stevens R.D. et al. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia. 2010; 53: 757–767. doi: 10.1007/s00125-009-1637-8.Tai E.S., Tan M.L., Stevens R.D. et al. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia. 2010; 53: 757–767. doi: 10.1007/s00125-009-1637-8.Batch B.C., Shah S.H., Newgard C.B. et al. Branched chain amino acids are novel biomarkers for discrimination of metabolic wellness. Metabolism. 2013; 62: 961–969. doi:10.1016/j.metabol.2013.01.007.Batch B.C., Shah S.H., Newgard C.B. et al. Branched chain amino acids are novel biomarkers for discrimination of metabolic wellness. Metabolism. 2013; 62: 961–969. doi:10.1016/j.metabol.2013.01.007.Wang T.J., Larson M.G., Vasan R.S. et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 2011; 17: 448–453. doi: 10.1038/nm.2307.Wang T.J., Larson M.G., Vasan R.S. et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 2011; 17: 448–453. doi: 10.1038/nm.2307.Shah S.H., Crosslin D.R., Haynes C.S. et al. Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. Diabetologia. 2012; 55: 321–330. doi: 10.1007/s00125-011-2356-5.Shah S.H., Crosslin D.R., Haynes C.S. et al. Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. Diabetologia. 2012; 55: 321–330. doi: 10.1007/s00125-011-2356-5.Laferrère B., Reilly D., Arias S., et al. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci. Transl. Med. 2011; 3: 80re2. doi:10.1126/scitranslmed.3002043.Laferrère B., Reilly D., Arias S., et al. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci. Transl. Med. 2011; 3: 80re2. doi:10.1126/scitranslmed.3002043.Newgard C.B. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 2012; 15: 606–614. doi:10.1016/j.cmet.2012.01.024.Newgard C.B. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 2012; 15: 606–614. doi:10.1016/j.cmet.2012.01.024.Shah S.H., Newgard C.B. Integrated metabolomics and genomics: systems approaches to biomarkers and mechanisms of cardiovascular disease. Circ. Cardiovasc. Genet. 2015; 8: 410–419. doi: 10.1161/CIRCGENETICS.114.000223.Shah S.H., Newgard C.B. Integrated metabolomics and genomics: systems approaches to biomarkers and mechanisms of cardiovascular disease. Circ. Cardiovasc. Genet. 2015; 8: 410–419. doi: 10.1161/CIRCGENETICS.114.000223.Shah S.H., Kraus W.E., Newgard C.B.. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation. 2012; 126: 1110–1120.doi: 10.1161/CIRCULATIONAHA.111.060368.Shah S.H., Kraus W.E., Newgard C.B.. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation. 2012; 126: 1110–1120.doi: 10.1161/CIRCULATIONAHA.111.060368.Shah S.H., Bain J.R., Muehlbauer M.J. et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ. Cardiovasc. Genet. 2010; 3: 207–214. doi: 10.1161/CIRCGENETICS.109.852814.Shah S.H., Bain J.R., Muehlbauer M.J. et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ. Cardiovasc. Genet. 2010; 3: 207–214. doi: 10.1161/CIRCGENETICS.109.852814.Ridaura V.K., Faith J.J., Rey F.E. et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013; 341: 1241214. doi: 10.1126/science.1241214.Ridaura V.K., Faith J.J., Rey F.E. et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013; 341: 1241214. doi: 10.1126/science.1241214.Feng Q., Liu Z., Zhong S. et al. “Integrated metabolomics and metagenomics analysis of plasma and urine identified microbial metabolites associated with coronary heart disease”. Scientific Reportsvol. 2016; 6: Article ID 22525.Feng Q., Liu Z., Zhong S. et al. “Integrated metabolomics and metagenomics analysis of plasma and urine identified microbial metabolites associated with coronary heart disease”. Scientific Reportsvol. 2016; 6: Article ID 22525.Jonsson A. L. and F. Backhed, “Role of gut microbiota in¨atherosclerosis,” Nature Reviews Cardiology. 2016; vol. 14, no. 2: 79–87.Jonsson A. L. and F. Backhed, “Role of gut microbiota in¨atherosclerosis,” Nature Reviews Cardiology. 2016; vol. 14, no. 2: 79–87.Wang Z., Klipfell E., Bennett B.J. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011; 472: 57–63. doi: 10.1038/nature09922.Wang Z., Klipfell E., Bennett B.J. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011; 472: 57–63. doi: 10.1038/nature09922.Tang W.H., Wang Z., Levison B.S. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl. J. Med. 2013; 368: 1575–1584. doi:10.1056/NEJMoa1109400.Tang W.H., Wang Z., Levison B.S. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl. J. Med. 2013; 368: 1575–1584. doi:10.1056/NEJMoa1109400.Senthong V., Wang Z., Fan Y. et al. Trimethylamine N -oxide and mortality risk in patients with peripheral artery disease. J. Am. Heart Assoc. 2016; 5: e004237.Senthong V., Wang Z., Fan Y. et al. Trimethylamine N -oxide and mortality risk in patients with peripheral artery disease. J. Am. Heart Assoc. 2016; 5: e004237.Tang W.H., Wang Z., Fan Y. et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am. Coll. Cardiol. 2014; 64: 1908–1914. doi:10.1016/j.jacc.2014.02.617.Tang W.H., Wang Z., Fan Y. et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am. Coll. Cardiol. 2014; 64: 1908–1914. doi:10.1016/j.jacc.2014.02.617.Tang W.H., Wang Z., Kennedy D.J. et al. Gut microbiota-dependent trimethylamineN-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ. Res. 2015; 116: 448–455. doi: 10.1161/CIRCRESAHA.116.305360.Tang W.H., Wang Z., Kennedy D.J. et al. Gut microbiota-dependent trimethylamineN-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ. Res. 2015; 116: 448–455. doi: 10.1161/CIRCRESAHA.116.305360.Organ C.L., Otsuka H., Bhushan S. et al. Choline diet and its gut microbe–derived metabolite, trimethylamine N-oxide, exacerbate pressure overload–induced heart failure. Circ. Hear. Fail. 2016; 9: e 002314.Organ C.L., Otsuka H., Bhushan S. et al. Choline diet and its gut microbe–derived metabolite, trimethylamine N-oxide, exacerbate pressure overload–induced heart failure. Circ. Hear. Fail. 2016; 9: e 002314.Senthong V., Wang Z., Li X.S. et al. Intestinal microbiota-generated metabolite trimethylamine-N-oxide and5-year mortality risk in stable coronary artery disease: the contributoryrole of intestinal microbiota in a COURAGE-like patient cohort. J. Am.Heart Assoc. 2016; 5: e002816.Senthong V., Wang Z., Li X.S. et al. Intestinal microbiota-generated metabolite trimethylamine-N-oxide and5-year mortality risk in stable coronary artery disease: the contributoryrole of intestinal microbiota in a COURAGE-like patient cohort. J. Am.Heart Assoc. 2016; 5: e002816.Undurti A., Huang Y., Lupica J.A. et al. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J. Biol. Chem. 2009; 284: 30825–30835. doi:10.1074/jbc.M109.047605.Undurti A., Huang Y., Lupica J.A. et al. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J. Biol. Chem. 2009; 284: 30825–30835. doi:10.1074/jbc.M109.047605.Wang Z., Roberts A.B., Buffa J.A. et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell. 2015;163: 1585–1595. doi: 10.1016/j.cell.2015.11.055.Wang Z., Roberts A.B., Buffa J.A. et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell. 2015;163: 1585–1595. doi: 10.1016/j.cell.2015.11.055.Gieger C., Geistlinger L., Altmaier E. et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet. 2008; 4: e1000282. doi: 10.1371/journal.pgen.1000282.Gieger C., Geistlinger L., Altmaier E. et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet. 2008; 4: e1000282. doi: 10.1371/journal.pgen.1000282.Illig T., Gieger C., Zhai G. et al. A genome-wide perspective of genetic variation in human metabolism. Nat. Genet. 2010; 42: 137–141. doi:10.1038/ng.507.Illig T., Gieger C., Zhai G. et al. A genome-wide perspective of genetic variation in human metabolism. Nat. Genet. 2010; 42: 137–141. doi:10.1038/ng.507.Suhre K., Shin S.Y., Petersen A.K. et al. CARDIoGRAM. Human metabolic individuality in biomedical and pharmaceutical research. Nature. 2011; 477: 54–60. doi: 10.1038/nature10354.Suhre K., Shin S.Y., Petersen A.K. et al. CARDIoGRAM. Human metabolic individuality in biomedical and pharmaceutical research. Nature. 2011; 477: 54–60. doi: 10.1038/nature10354.Rhee E.P., Ho J.E., Chen M.H. et al. A genome-wide association study of the human metabolome in a community-based cohort. Cell Metab. 2013; 18: 130–143. doi: 10.1016/j.cmet.2013.06.013.Rhee E.P., Ho J.E., Chen M.H. et al. A genome-wide association study of the human metabolome in a community-based cohort. Cell Metab. 2013; 18: 130–143. doi: 10.1016/j.cmet.2013.06.013.Draisma H.H.M., Pool R., Kobl M. et al. Genome-wide associationstudy identifies novel genetic variants contributing to variation inblood metabolite levels. Nat Commun. 2015; 6: 7208. doi: 10.1038/ncomms8208.Draisma H.H.M., Pool R., Kobl M. et al. Genome-wide associationstudy identifies novel genetic variants contributing to variation inblood metabolite levels. Nat Commun. 2015; 6: 7208. doi: 10.1038/ncomms8208.Bennett B.J., de Aguiar Vallim T.Q., Wang Z. et al. Trimethylamine-Noxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013; 17: 49–60. doi: 10.1016/j.cmet.2012.12.011.Bennett B.J., de Aguiar Vallim T.Q., Wang Z. et al. Trimethylamine-Noxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013; 17: 49–60. doi: 10.1016/j.cmet.2012.12.011.Kraus W.E., Muoio D.M., Stevens R. et al. Metabolomic quantitative trait loci (mQTL) mapping implicates the ubiquitin proteasome system in cardiovascular disease pathogenesis. PLoS Genet. 2015; 11: e1005553. doi:10.1371/journal.pgen.1005553.Kraus W.E., Muoio D.M., Stevens R. et al. Metabolomic quantitative trait loci (mQTL) mapping implicates the ubiquitin proteasome system in cardiovascular disease pathogenesis. PLoS Genet. 2015; 11: e1005553. doi:10.1371/journal.pgen.1005553.Mayr M., Madhu B., Xu Q. Proteomics and metabolomics combined in cardiovascular research. Trends Cardiovasc. Med. 2007; 17: 43–48. doi:10.1016/j.tcm.2006.11.004.Mayr M., Madhu B., Xu Q. Proteomics and metabolomics combined in cardiovascular research. Trends Cardiovasc. Med. 2007; 17: 43–48. doi:10.1016/j.tcm.2006.11.004.Mayr M., Chung Y.L., Mayr U. et al. Loss of PKC-delta alters cardiac metabolism. Am. J. Physiol. Heart Circ. Physiol. 2004. 287. P. 937–945. doi:10.1152/ajpheart.00877.2003.Mayr M., Chung Y.L., Mayr U. et al. Loss of PKC-delta alters cardiac metabolism. Am. J. Physiol. Heart Circ. Physiol. 2004. 287. P. 937–945. doi:10.1152/ajpheart.00877.2003.Mayr M., Metzler B., Chung Y.L., et al. Ischemic preconditioning exaggerates cardiac damage in PKC-delta null mice. Am J Physiol Heart Circ Physiol. 2004; 287: 946–956. doi:10.1152/ajpheart.00878.2003.Mayr M., Metzler B., Chung Y.L., et al. Ischemic preconditioning exaggerates cardiac damage in PKC-delta null mice. Am J Physiol Heart Circ Physiol. 2004; 287: 946–956. doi:10.1152/ajpheart.00878.2003.Mayr M., Liem D., Zhang J. et al. Proteomic and metabolomic analysis of cardioprotection: interplay between protein kinase C epsilon and delta in regulating glucose metabolism of murine hearts. J. Mol. Cell Cardiol. 2009; 46: 268–277. doi:10.1016/j.yjmcc.2008.10.008.Mayr M., Liem D., Zhang J. et al. Proteomic and metabolomic analysis of cardioprotection: interplay between protein kinase C epsilon and delta in regulating glucose metabolism of murine hearts. J. Mol. Cell Cardiol. 2009; 46: 268–277. doi:10.1016/j.yjmcc.2008.10.008.Mayr M., Chung Y.L., Mayr U. et al. Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 2135–2142. doi: 10.1161/01.ATV.0000183928.25844.f6.Mayr M., Chung Y.L., Mayr U. et al. Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 2135–2142. doi: 10.1161/01.ATV.0000183928.25844.f6.Perez-Riverol Y., Bai M., da Veiga Leprevost F. et al. Discovering and linking public omics data sets using the Omics Discovery Index. Nat. Biotechnol. 2017; 3: 406–409. doi: 10.1038/nbt.3790.Perez-Riverol Y., Bai M., da Veiga Leprevost F. et al. Discovering and linking public omics data sets using the Omics Discovery Index. Nat. Biotechnol. 2017; 3: 406–409. doi: 10.1038/nbt.3790.Noor Elad, Cherkaoui Sarah and Sauer Uwe. Biological insights through omics data integration. Current Opinion in Systems Biology. 2019; 15: 39–47. https://doi.org/10.1016/j.coisb.2019.03.007Noor Elad, Cherkaoui Sarah and Sauer Uwe. Biological insights through omics data integration. Current Opinion in Systems Biology. 2019; 15: 39–47. https://doi.org/10.1016/j.coisb.2019.03.007Petersen A.K., Zeilinger S., Kastenmüller G. et al. Epigenetics meets metabolomics: an epigenome-wide association study with blood serum metabolic traits. Hum. Mol. Genet. 2014. 23. P. 534–545. doi:10.1093/hmg/ddt430.Petersen A.K., Zeilinger S., Kastenmüller G. et al. Epigenetics meets metabolomics: an epigenome-wide association study with blood serum metabolic traits. Hum. Mol. Genet. 2014. 23. P. 534–545. doi:10.1093/hmg/ddt430.Cook D.J., Nielsen J. Genome-scale metabolic models applied to human health and disease. Wiley Interdiscip Rev. Syst. Biol. Med. 2017; 9: 1393.Cook D.J., Nielsen J. Genome-scale metabolic models applied to human health and disease. Wiley Interdiscip Rev. Syst. Biol. Med. 2017; 9: 1393.Duarte N.C., Becker S.A., Jamshidi N., et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci USA. 2007; 104: 1777–1782. doi: 10.1073/pnas.0610772104.Duarte N.C., Becker S.A., Jamshidi N., et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci USA. 2007; 104: 1777–1782. doi: 10.1073/pnas.0610772104.Karlstädt A., Fliegner D., Kararigas G. et al. CardioNet: a human metabolic network suited for the study of cardiomyocyte metabolism. BMC Syst Biol. 2012; 6: 114. doi:10.1186/1752-0509-6-114.Karlstädt A., Fliegner D., Kararigas G. et al. CardioNet: a human metabolic network suited for the study of cardiomyocyte metabolism. BMC Syst Biol. 2012; 6: 114. doi:10.1186/1752-0509-6-114.Karlstaedt A., Zhang X., Vitrac H. et al. Oncometabolite d-2-hydroxyglutarateimpairs α-ketoglutarate dehydrogenase and contractile function in rodent heart. Proc. Natl. Acad. Sci. USA. 2016; 113: 10436–10441. doi:10.1073/pnas.1601650113.Karlstaedt A., Zhang X., Vitrac H. et al. Oncometabolite d-2-hydroxyglutarateimpairs α-ketoglutarate dehydrogenase and contractile function in rodent heart. Proc. Natl. Acad. Sci. USA. 2016; 113: 10436–10441. doi:10.1073/pnas.1601650113.Chan S.Y., Loscalzo J. The emerging paradigm of network medicine in the study of human disease. Circ. Res. 2012; 111: 359–374. doi:10.1161/CIRCRESAHA.111.258541.Chan S.Y., Loscalzo J. The emerging paradigm of network medicine in the study of human disease. Circ. Res. 2012; 111: 359–374. doi:10.1161/CIRCRESAHA.111.258541.

The authors declare that there are no conflicts of interest present.